Ubs Group Ag Prothena Corp Public LTD CO Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in Prothena Corp Public LTD CO stock. As of the latest transaction made, Ubs Group Ag holds 62,506 shares of PRTA stock, worth $951,341. This represents 0.0% of its overall portfolio holdings.

Number of Shares

62,506

Previous 44,768 39.62%

Holding current value

$951,341

Previous $924,000 13.1%

% of portfolio

0.0%

Previous 0.0%

31 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$16.73 - $24.79 $296,756 - $439,725	17,738 Added 39.62%	62,506 $1.05 Million
Q2 2024 Aug 13, 2024	SELL	$19.54 - $26.15 $3.01 Million - $4.02 Million	-153,912 Reduced 77.47%	44,768 $924,000
Q1 2024 May 13, 2024	BUY	$24.75 - $40.66 $1.64 Million - $2.69 Million	66,183 Added 49.95%	198,680 $4.92 Million
Q4 2023 Feb 09, 2024	BUY	$32.31 - $52.32 $2.82 Million - $4.56 Million	87,245 Added 192.8%	132,497 $4.81 Million
Q3 2023 Nov 09, 2023	BUY	$47.3 - $70.6 $1.08 Million - $1.62 Million	22,877 Added 102.24%	45,252 $2.18 Million
Q2 2023 Aug 11, 2023	SELL	$48.26 - $78.59 $1.9 Million - $3.09 Million	-39,268 Reduced 63.7%	22,375 $1.53 Million
Q1 2023 May 12, 2023	SELL	$46.97 - $58.27 $1.38 Million - $1.71 Million	-29,426 Reduced 32.31%	61,643 $2.99 Million
Q4 2022 Feb 08, 2023	BUY	$52.05 - $65.0 $4.42 Million - $5.52 Million	84,920 Added 1381.04%	91,069 $5.49 Million
Q3 2022 Nov 10, 2022	SELL	$25.16 - $60.63 $369,197 - $889,684	-14,674 Reduced 70.47%	6,149 $373,000
Q2 2022 Aug 10, 2022	SELL	$22.73 - $39.98 $627,257 - $1.1 Million	-27,596 Reduced 56.99%	20,823 $566,000
Q1 2022 May 16, 2022	SELL	$30.27 - $49.22 $785,597 - $1.28 Million	-25,953 Reduced 34.9%	48,419 $1.77 Million
Q4 2021 Feb 14, 2022	SELL	$42.11 - $73.26 $132,435 - $230,402	-3,145 Reduced 4.06%	74,372 $3.67 Million
Q3 2021 Nov 15, 2021	BUY	$48.2 - $78.89 $3.66 Million - $5.98 Million	75,855 Added 4564.08%	77,517 $5.52 Million
Q2 2021 Aug 13, 2021	SELL	$21.63 - $57.65 $485,031 - $1.29 Million	-22,424 Reduced 93.1%	1,662 $85,000
Q1 2021 May 12, 2021	BUY	$11.0 - $28.24 $170,093 - $436,675	15,463 Added 179.32%	24,086 $605,000
Q4 2020 Feb 11, 2021	BUY	$10.12 - $13.94 $79,067 - $108,913	7,813 Added 964.57%	8,623 $104,000
Q3 2020 Nov 12, 2020	SELL	$9.93 - $13.47 $9,850 - $13,362	-992 Reduced 55.05%	810 $8,000
Q2 2020 Jul 31, 2020	SELL	$9.56 - $12.51 $155,655 - $203,687	-16,282 Reduced 90.04%	1,802 $18,000
Q1 2020 May 01, 2020	SELL	$7.54 - $15.77 $164,160 - $343,344	-21,772 Reduced 54.63%	18,084 $193,000
Q4 2019 Feb 14, 2020	SELL	$7.48 - $17.01 $154,656 - $351,698	-20,676 Reduced 34.16%	39,856 $631,000
Q3 2019 Nov 14, 2019	BUY	$6.89 - $10.45 $279,024 - $423,193	40,497 Added 202.13%	60,532 $475,000
Q2 2019 Aug 14, 2019	BUY	$8.85 - $12.49 $139,714 - $197,179	15,787 Added 371.63%	20,035 $211,000
Q1 2019 May 14, 2019	SELL	$10.32 - $14.49 $1.29 Million - $1.82 Million	-125,477 Reduced 96.73%	4,248 $51,000
Q4 2018 Feb 14, 2019	BUY	$8.73 - $13.74 $1.05 Million - $1.65 Million	120,072 Added 1243.88%	129,725 $1.34 Million
Q3 2018 Nov 14, 2018	SELL	$12.7 - $15.79 $25,971 - $32,290	-2,045 Reduced 17.48%	9,653 $126,000
Q2 2018 Aug 14, 2018	SELL	$10.99 - $44.21 $797,115 - $3.21 Million	-72,531 Reduced 86.11%	11,698 $171,000
Q1 2018 May 15, 2018	BUY	$27.95 - $45.04 $1.86 Million - $2.99 Million	66,400 Added 372.43%	84,229 $3.09 Million
Q4 2017 Feb 14, 2018	SELL	$35.44 - $63.76 $556,762 - $1 Million	-15,710 Reduced 46.84%	17,829 $669,000
Q3 2017 Nov 14, 2017	BUY	$53.83 - $67.75 $282,930 - $356,094	5,256 Added 18.58%	33,539 $2.17 Million
Q2 2017 Aug 14, 2017	BUY	N/A	1,968 Added 7.48%	28,283 $1.53 Million
Q1 2017 Nov 14, 2017	BUY	N/A	26,315	26,315 $1.47 Million

Others Institutions Holding PRTA

# of Institutions

184

Shares Held

42.7M

Call Options Held

162K

Put Options Held

102K

View Full List

About PROTHENA CORP PUBLIC LTD CO

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $714M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

More about PRTA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account